Cited by 371SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing

The DOI matches its Crossref record; 8 of the 10 references it cites were found in a registry or an index.

Emergence of a Novel SARS-CoV-2 Variant in Southern California

Open access

Zhang, Wenjuan, Davis, Brian D., Chen, Stephanie S., Sincuir Martinez, Jorge M., Plummer, Jasmine T., Vail, Eric·2021·JAMA

DOI 10.1001/jama.2021.1612PMC PMC7879386

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

This research describes findings of sequencing and phylogenetic analyses of SARS-CoV-2 isolates from symptomatic patients cared for at Cedar-Sinai Medical Center in November-December 2020 during a regional surge in cases and hospitalizations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jama.2021.1612

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nextstrain: real-time tracking of pathogen evolution
Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P., Bedford, T., & Neher, R. A. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty407 · Cited by 3,154
GISAID: Global initiative on sharing all influenza data – from vision to reality
Shu, Y., & McCauley, J. (2017) · Eurosurveillance · doi:10.2807/1560-7917.es.2017.22.13.30494 · Cited by 3,039
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.012 · Cited by 1,420
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
Genetic Variants of SARS-CoV-2—What Do They Mean?
Lauring, A. S., & Hodcroft, E. B. (2021) · JAMA · doi:10.1001/jama.2020.27124 · Cited by 604
Emergence of a new SARS-CoV-2 variant in the UK
Tang, J. W.-T., Tambyah, P. A., & Hui, D. S. C. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.12.024 · Cited by 273
Analysis of Genomic Characteristics and Transmission Routes of Patients With Confirmed SARS-CoV-2 in Southern California During the Early Stage of the US COVID-19 Pandemic
Zhang, W., Govindavari, J. P., Davis, B. D., Chen, S. S., Kim, J. T., Song, J., Lopategui, J. R., Plummer, J., & Vail, E. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.24191 · Cited by 36
Self-citation
S gene dropout patterns in SARS-CoV-2 tests suggest spread of the H69del/V70del mutation in the USPreprint
Washington, N. L., White, S. J., Barrett, K. M. S., Cirulli, E. T., Bolze, A., & Lu, J. T. (2020) · medRxiv · doi:10.1101/2020.12.24.20248814 · Cited by 35

Show all 10 references

Sorted by citations

Features, Evaluation and Treatment Coronavirus (COVID-19)
Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., & Napoli, R. D. (2020) · StatPearls · Cited by 3,351
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2022) · Nature · doi:10.1038/s41586-021-04388-0 · Cited by 1,290
Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals
Tarke, A., Sidney, J., Methot, N., Yu, E. D., Zhang, Y., Dan, J. M., Goodwin, B., Rubiro, P., Sutherland, A., Wang, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100355 · Cited by 706
Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.025 · Cited by 651
SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity
Motozono, C., Toyoda, M., Zahradnik, J., Saito, A., Nasser, H., Tan, T. S., Ngare, I., Kimura, I., Uriu, K., Kosugi, Y., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.006 · Cited by 586
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Starr, T. N., Czudnochowski, N., Liu, Z., Zatta, F., Park, Y., Addetia, A., Pinto, D., Beltramello, M., Hernandez, P., Greaney, A. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03807-6 · Cited by 503
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
Starr, T. N., Greaney, A. J., Dingens, A. S., & Bloom, J. D. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100255 · Cited by 470
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C., Cho, A., Agudelo, M., Finkin, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24435-8 · Cited by 433
Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19)
Aleem, A., Samad, A., & Slenker, A. K. (2021) · Europe PMC (PubMed Central) · Cited by 398
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Sanders, K. O., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.002 · Cited by 378
Novel SARS-CoV-2 variants: the pandemics within the pandemic
Boehm, E., Kronig, I., Neher, R. A., Eckerle, I., Vetter, P., & Kaiser, L. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.022 · Cited by 346
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
Alter, G., Yu, J., Liu, J., Chandrashekar, A., Borducchi, E. N., Tostanoski, L. H., McMahan, K., Jacob-Dolan, C., Martinez, D. R., Chang, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03681-2 · Cited by 304
On the origin and evolution of SARS-CoV-2
Singh, D., & Yi, S. V. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00604-z · Cited by 281
Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19
Gómez, C. E., Perdiguero, B., & Estéban, M. (2021) · Vaccines · doi:10.3390/vaccines9030243 · Cited by 267
Ongoing global and regional adaptive evolution of SARS-CoV-2
Rochman, N. D., Wolf, Y. I., Faure, G., Mutz, P., Zhang, F., & Koonin, E. V. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2104241118 · Cited by 243
Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation
Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · doi:10.1101/2021.03.07.21252647 · Cited by 651
“88 In January 2021, we and others independently reported the emergence of a 89 novel variant in California carrying an L452R mutation in the RBD of the spike protein 90 (CDPH, 2021; Zhang et al., 2021).”
Background
Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection
Greaney, A. J., Loes, A. N., Gentles, L. E., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi9915 · Cited by 244
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
Shen, X., Tang, H., Pajon, R., Smith, G., Glenn, G. M., Shi, W., Korber, B., & Montefiori, D. C. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2103740 · Cited by 193
SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants
Moore, J. P., & Offit, P. A. (2021) · JAMA · doi:10.1001/jama.2021.1114 · Cited by 220
Emerging SARS-CoV-2 variants of concern and potential intervention approaches
Khateeb, J., Li, Y., & Zhang, H. (2021) · Critical Care · doi:10.1186/s13054-021-03662-x · Cited by 231
Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants
Tchesnokova, V. L., Kulasekara, H. D., Larson, L., Bowers, V., Rechkina, E., Kisiela, D., Sledneva, Y., Choudhury, D., Maslova, I., Deng, K., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00921-21 · Cited by 214
Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries
Wang, R., Chen, J., Gao, K., & Wei, G.-W. (2021) · Genomics · doi:10.1016/j.ygeno.2021.05.006 · Cited by 191
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies
Copin, R., Baum, A., Wloga, E., Pascal, K. E., Giordano, S., Fulton, B. O., Zhou, A., Negron, N., Lanza, K., Chan, N., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.002 · Cited by 212
Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe
Thakur, V., Bhola, S., Thakur, P., Patel, S. K. S., Kulshrestha, S., Ratho, R. K., & Kumar, P. (2022) · Infection · doi:10.1007/s15010-021-01734-2 · Cited by 195
“V1) variant first identified in California, the USA in 2021, showed a 20% increase in transmission possibly attributed to the L452R and D614G substitutions in the spike protein [36].”
Background
Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike
Lubinski, B., Fernandes, M. H. V., Frazier, L. E., Tang, T., Daniel, S., Diel, D. G., Jaimes, J. A., & Whittaker, G. R. (2021) · iScience · doi:10.1016/j.isci.2021.103589 · Cited by 209
The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape
Tian, D., Sun, Y., Zhou, J., & Ye, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.751778 · Cited by 201
SARS-CoV-2 Mutations and their Viral Variants
Coşar, B., KARAGÜLLEOĞLU, Z. Y., ÜNAL, S., İnce, A. T., Uncuoglu, D. B., Tuncer, G., Kilinc, B. R., Ozkan, Y. E., Ozkoc, H. C., Demir, I. N., et al. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.06.001 · Cited by 205
Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?
Vasireddy, D., Vanaparthy, R., Mohan, G., Malayala, S. V., & Atluri, P. (2021) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4518 · Cited by 197
Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?
Lazarević, I., Pravica, V., Miljanovic, D., & Cupic, M. D. (2021) · Viruses · doi:10.3390/v13071192 · Cited by 193
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies
Raman, R., Patel, K. J., & Ranjan, K. (2021) · Biomolecules · doi:10.3390/biom11070993 · Cited by 194
Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies
Bian, L., Gao, F., Zhang, J., He, Q., Mao, Q., Xu, M., & Liang, Z. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1903879 · Cited by 183
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial
Li, J., Wu, S., Guo, X., Tang, R., Huang, B., Chen, X., Chen, Y., Hou, L.-H., Liu, J.-X., Zhong, J., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00087-x · Cited by 166
SARS-CoV-2 Viral Variants—Tackling a Moving Target
Mascola, J. R., Graham, B. S., & Fauci, A. S. (2021) · JAMA · doi:10.1001/jama.2021.2088 · Cited by 163
Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy
Ramesh, S., Govindarajulu, M., Parise, R. S., Neel, L. T., Shankar, T., Patel, S., Lowery, P., Smith, F., Dhanasekaran, M., & Moore, T. (2021) · Vaccines · doi:10.3390/vaccines9101195 · Cited by 157
SARS-CoV-2 one year on: evidence for ongoing viral adaptation
Peacock, T. P., Penrice-Randal, R., Hiscox, J. A., & Barclay, W. (2021) · Journal of General Virology · doi:10.1099/jgv.0.001584 · Cited by 155
Neutralising antibody escape of SARS‐CoV‐2 spike protein: Risk assessment for antibody‐based Covid‐19 therapeutics and vaccines
Focosi, D., & Maggi, F. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2231 · Cited by 150
Emerging Biosensing Technologies for the Diagnostics of Viral Infectious Diseases
Kabay, G., DeCastro, J., Altay, A., Smith, K., Lu, H., Capossela, A. M., Moarefian, M., Aran, K., & Dincer, C. (2022) · Advanced Materials · doi:10.1002/adma.202201085 · Cited by 148
Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2Preprint
Liu, L., Iketani, S., Guo, Y., Chan, J. F., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.14.472719 · Cited by 142
Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
Becker, M., Dulovic, A., Junker, D., Ruétalo, N., Kaiser, P. D., Pinilla, Y. T., Heinzel, C., Häring, J., Traenkle, B., Wagner, T. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23473-6 · Cited by 137
Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines
Zhou, W., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00644-x · Cited by 134
Collapse of the public health system and the emergence of new variants during the second wave of the COVID-19 pandemic in Brazil
da Silva, S. J. R., & Pena, L. (2021) · One Health · doi:10.1016/j.onehlt.2021.100287 · Cited by 147
SARS-CoV-2 immune evasion by variant B.1.427/B.1.429Preprint
McCallum, M., Bassi, J., Marco, A. D., Chen, A., Walls, A. C., di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.31.437925 · Cited by 128
The emerging SARS-CoV-2 variants of concern
Sanyaolu, A. O., Okorie, C., Marinkovic, A., Haider, N., Abbasi, A. F., Jaferi, U., Prakash, S., & Balendra, V. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211024372 · Cited by 122
Detection of SARS-CoV-2 variants by genomic analysis of wastewater samples in Israel
Bar-Or, I., Weil, M., Indenbaum, V., Bucris, E. D., Bar-Ilan, D., Elul, M., Levi, N., Aguvaev, I., Cohen, Z. R., Shirazi, R., et al. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.148002 · Cited by 112
Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
Jette, C. A., Cohen, A. A., Gnanapragasam, P. N. P., Muecksch, F., Lee, Y. E., Huey‐Tubman, K. E., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M. C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109760 · Cited by 99
Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S‐glycoprotein, infectivity, re‐infectivity, immune escape and vaccines activity
Chakraborty, C., Bhattacharya, M., & Sharma, A. R. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2270 · Cited by 111
An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines
Hillary, V. E., & Ceasar, S. A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13952 · Cited by 121
Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants
Sah, P., VILCHES, T. N., Moghadas, S. M., Fitzpatrick, M. C., Singer, B. H., Hotez, P. J., & Galvani, A. P. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100865 · Cited by 108
Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions
Abulsoud, A. I., El‐Husseiny, H. M., El-Husseiny, A. A., El‐Mahdy, H. A., Ismail, A., Elkhawaga, S. Y., Khidr, E. G., Fathi, D., Mady, E. A., Najda, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113977 · Cited by 112
Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany
Aziz, N. A., Corman, V. M., Echterhoff, A. K. C., Müller, M. A., Richter, A. M., Schmandke, A., Schmidt, M. L., Schmidt, T. H., de Vries, F. M., Drosten, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22351-5 · Cited by 107
Nanoemulsions: Formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks
Tayeb, H. H., Felimban, R. I., Almaghrabi, S. A., & Hasaballah, N. H. (2021) · Colloids and Interface Science Communications · doi:10.1016/j.colcom.2021.100533 · Cited by 112
The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern
Akkız, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.849217 · Cited by 102
Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor
Liu, J., Bodnar, B. H., Meng, F., Khan, A. I., Wang, X., Luo, G. G., Saribas, S., Wang, T., Lohani, S. C., Wang, P., et al. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00680-8 · Cited by 97
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
Bertoglio, F., Fühner, V., Ruschig, M., Heine, P. A., Abassi, L., Klünemann, T., Rand, U., Meier, D., Langreder, N., Steinke, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109433 · Cited by 98
Multiplex SARS-CoV-2 Genotyping Reverse Transcriptase PCR for Population-Level Variant Screening and Epidemiologic Surveillance
Wang, H., Miller, J. A., Verghese, M., Sibai, M., Solis, D., Mfuh, K. O., Jiang, B., Iwai, N., Mar, M., Huang, C., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00859-21 · Cited by 93
Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York
West, A. P., Wertheim, J. O., Wang, J. C., Vasylyeva, T. I., Havens, J. L., Chowdhury, M. A., Gonzalez, E., Fang, C. E., Lonardo, S. S. D., Hughes, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25168-4 · Cited by 134
Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern
Kim, S., Liu, Y., Lei, Z., Dicker, J., Cao, Y., Zhang, X. F., & Im, W. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00965 · Cited by 90
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update
Anand, U., Jakhmola, S., Indari, O., Jha, H. C., Chen, Z., Tripathi, V. S., & de la Lastra, J. M. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658519 · Cited by 84
Lineage abundance estimation for SARS-CoV-2 in wastewater using transcriptome quantification techniques
Baaijens, J. A., Zulli, A., Ott, I. M., Nika, I., van der Lugt, M. J., Petrone, M. E., Alpert, T., Fauver, J. R., Kalinich, C. C., Vogels, C. B. F., et al. (2022) · Genome biology · doi:10.1186/s13059-022-02805-9 · Cited by 73
Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion
Salleh, M. Z., Derrick, J. P., & Deris, Z. Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147425 · Cited by 82
Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
Shrestha, L. B., Tedla, N. T., & Bull, R. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752003 · Cited by 78
Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2
Chen, C., Boorla, V. S., Banerjee, D., Chowdhury, R., Cavener, V. S., Nissly, R. H., Gontu, A., Boyle, N. R., Vandegrift, K. J., Nair, M. S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106480118 · Cited by 81
Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review
Das, S., Kar, S. S., Samanta, S., Banerjee, J., Giri, B., & Dash, S. K. (2022) · Immunologic Research · doi:10.1007/s12026-022-09265-0 · Cited by 82
Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
Cerutti, G., Guo, Y., Wang, P., Nair, M. S., Wang, M., Huang, Y., Yu, J., Liu, L., Katsamba, P. S., Bahna, F. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109928 · Cited by 63
Mutation-Specific SARS-CoV-2 PCR Screen: Rapid and Accurate Detection of Variants of Concern and the Identification of a Newly Emerging Variant with Spike L452R Mutation
Wang, H., Jean, S., Eltringham, R., Madison, J., Snyder, P. J., Tu, H., Jones, D. M., & Leber, A. L. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00926-21 · Cited by 72
Measuring infectious SARS-CoV-2 in clinical samples reveals a higher viral titer:RNA ratio for Delta and Epsilon vs. Alpha variants
Despres, H. W., Mills, M. G., Shirley, D. J., Schmidt, M. M., Huang, M.-L. W., Roychoudhury, P., Jerome, K. R., Greninger, A. L., & Bruce, E. A. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116518119 · Cited by 65
Acute SARS-CoV-2 infection is associated with an increased abundance of bacterial pathogens, including Pseudomonas aeruginosa in the nose
Rhoades, N. S., Pinski, A. N., Monsibais, A. N., Jankeel, A., Doratt, B. M., Cinco, I. R., Ibraim, I. C., & Messaoudi, I. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109637 · Cited by 73
An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
Tanaka, S., Nelson, G., Olson, C. A., Buzko, O. V., Higashide, W., Shin, A., Gonzalez, M. R., Taft, J. D., Patel, R. S., Buta, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91809-9 · Cited by 65
Controversy surrounding the Sputnik V vaccine
Cazzola, M., Rogliani, P., Mazzeo, F., & Matera, M. G. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106569 · Cited by 66
SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence
Tatsi, E., Filippatos, F., & Michos, A. G. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821002430 · Cited by 68
Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern
Shahhosseini, N., Babuadze, G. G., Wong, G., & Kobinger, G. (2021) · Microorganisms · doi:10.3390/microorganisms9050926 · Cited by 66
Use of wastewater surveillance for early detection of Alpha and Epsilon SARS-CoV-2 variants of concern and estimation of overall COVID-19 infection burden
Vo, V., Tillett, R. L., Papp, K., Shen, S., Gu, R., Gorzalski, A. J., Siao, D. D., Markland, R., Chang, C.-L., Baker, H., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.155410 · Cited by 60
A Simple Reverse Transcriptase PCR Melting-Temperature Assay To Rapidly Screen for Widely Circulating SARS-CoV-2 Variants
Banada, P. P., Green, R., Banik, S., Chopoorian, A., Streck, D. L., Jones, R., Chakravorty, S., & Alland, D. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00845-21 · Cited by 61
Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center
Jacobson, K. B., Pinsky, B. A., Montez Rath, M. E., Wang, H., Miller, J. A., Skhiri, M., Shepard, J., Mathew, R., Lee, G., Bohman, B., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab554 · Cited by 62
Recent Chronology of COVID-19 Pandemic
Siddiqui, S., Alhamdi, H. W. S., & Alghamdi, H. A. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.778037 · Cited by 80
Molecular Aspects Concerning the Use of the SARS-CoV‑2 Receptor Binding Domain as a Target for Preventive Vaccines
Valdés-Balbín, Y., Santana-Mederos, D., Paquet, F., Fernández-Castillo, S., Climent, Y., Chiodo, F., Rodríguez, L., Ramírez, B. S., León, K., Hernández, T., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00216 · Cited by 53
Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity
Bradley, B. T., Bryan, A. B., Fink, S. L., Goecker, E. A., Roychoudhury, P., Huang, M.-L. W., Zhu, H., Chaudhary, A., Madarampalli, B., Lu, J., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00989-21 · Cited by 55
Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients
Slezak, J. M., Bruxvoort, K. J., Fischer, H. J., Broder, B. I., Ackerson, B. K., & Tartof, S. Y. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.07.030 · Cited by 60
Spike2Vec: An Efficient and Scalable Embedding Approach for COVID-19 Spike Sequences
Ali, S., & Patterson, M. (2021) · IEEE International Conference on Big Data (BigData) · doi:10.1109/bigdata52589.2021.9671848 · Cited by 59
Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New YorkPreprint
West, A. P., Wertheim, J. O., Wang, J. C., Vasylyeva, T. I., Havens, J. L., Chowdhury, M. A., Gonzalez, E., Fang, C. E., Lonardo, S. S. D., Hughes, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.14.431043 · Cited by 74
Insights into SARS-CoV-2 Persistence and Its Relevance
Desimmie, B. A., Raru, Y., Awadh, H., He, P., Teka, S., & Willenburg, K. S. (2021) · Viruses · doi:10.3390/v13061025 · Cited by 58
Analysis of the Potential Efficacy and Timing of COVID-19 Vaccine on Morbidity and Mortality
Haghpanah, F., Lin, G., Levin, S. A., & Klein, E. Y. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100863 · Cited by 57
Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
Lou, F., Li, M., Pang, Z., Jiang, L., Guan, L., Tian, L., Hu, J., Fan, J., & Fan, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744242 · Cited by 54
SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines
Singh, D. D., Parveen, A., & Yadav, D. K. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.777212 · Cited by 52
Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry
Qing, E., Li, P., Cooper, L. M., Schulz, S. R., Jäck, H., Rong, L., Perlman, S. M., & Gallagher, T. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110786 · Cited by 45
Lung fibrosis: Post-COVID-19 complications and evidences
Hirawat, R., Jain, N., Saifi, M. A., Rachamalla, M., & Godugu, C. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109418 · Cited by 54
One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening
Francino-Urdaniz, I. M., Steiner, P. J., Kirby, M. B., Zhao, F., Haas, C. M., Barman, S., Rhodes, E. R., Leonard, A. C., Peng, L., Sprenger, K. G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109627 · Cited by 47
SARS-CoV-2 spike protein: structure, viral entry and variants
Chen, B., Farzan, M., & Choe, H. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01185-8 · Cited by 57
SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity
Huang, S., & Wang, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063060 · Cited by 50
Understanding mutation hotspots for the SARS-CoV-2 spike protein using Shannon Entropy and K-means clustering
Mullick, B., Magar, R., Jhunjhunwala, A., & Farimani, A. B. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104915 · Cited by 49
Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs
Stoddard, C. I., Galloway, J., Chu, H. Y., Shipley, M. M., Sung, K., Itell, H. L., Wolf, C. R., Logue, J. K., Magedson, A., Garrett, M. E., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109164 · Cited by 52
COVID-19, the first pandemic in the post-genomic era
van Dorp, L., Houldcroft, C. J., Richard, D., & Balloux, F. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.07.002 · Cited by 49
SARS‐CoV‐2 virulence evolution: Avirulence theory, immunity and trade‐offs
Alizon, S., & Sofonea, M. T. (2021) · Journal of Evolutionary Biology · doi:10.1111/jeb.13896 · Cited by 53
Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions
Cheng, M. H., Krieger, J., Banerjee, A., Xiang, Y., Kaynak, B., Shi, Y., Arditi, M., & Bahar, İ. (2022) · iScience · doi:10.1016/j.isci.2022.103939 · Cited by 50
Sequence Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern
Long, S. W., Olsen, R. J., Christensen, P. A., Subedi, S., Olson, R., Davis, J. J., Saavedra, M. O., Yerramilli, P., Pruitt, L., Reppond, K., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.03.004 · Cited by 46
SARS-CoV-2 Genome Sequencing Methods Differ in Their Abilities To Detect Variants from Low-Viral-Load Samples
Lam, C., Gray, K.-A., Gall, M. L., Sadsad, R., Arnott, A., Johnson-Mackinnon, J. C., Fong, W., Basile, K., Kok, J., Dwyer, D. E., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01046-21 · Cited by 47
Molecular insights into the adaptive evolution of SARS-CoV-2 spike protein
Yao, Z., Zhang, L., Duan, Y., Tang, X., & Lü, J. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106121 · Cited by 49
The Development of SARS-CoV-2 Variants: The Gene Makes the Disease
Pérez-Gómez, R. (2021) · Journal of Developmental Biology · doi:10.3390/jdb9040058 · Cited by 47
Detection of SARS-CoV-2 B.1.351 (Beta) Variant through Wastewater Surveillance before Case Detection in a Community, Oregon, USA
Sutton, M., Radniecki, T. S., Kaya, D., Alegre, D., Geniza, M. J., Girard, A.-M., Carter, K., Dasenko, M., Sanders, J. L., Cieslak, P. R., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2806.211821 · Cited by 45
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies
Focosi, D., McConnell, S. A., & Casadevall, A. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100882 · Cited by 45

Authors: Zhang, W., Davis, B. D., Chen, S. S., Sincuir Martinez, J. M., Plummer, J. T., & Vail, E.
Affiliations: Cedars-Sinai Medical Center (US)
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California
Corresponding author: Plummer, Jasmine T.
ORCID: Zhang, Wenjuan
Davis, Brian D.
Plummer, Jasmine T.
Vail, Eric
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2021-04-06
Volume: 325
Issue: 13
Pages: 1324
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2021.1612
PMC: PMC7879386
OpenAlex: W3127156551
Cited by: 371
References: 10
Citations by year: 2026: 2 · 2025: 7 · 2024: 19 · 2023: 21 · 2022: 86 · 2021: 232
FWCI: 28.34
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: other-oa
Locations: JAMA (publishedVersion, other-oa)
medRxiv (acceptedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Keywords: SARS-CoV-2, COVID-19 pandemic, novel variants, viral variant emergence, phylogenetic analysis, viral genome sequencing, symptomatic patients, Southern California
MeSH terms: COVID-19, SARS-CoV-2, California, Humans, Mutation, Sequence Analysis, RNA, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Emergence of a Novel SARS-CoV-2 Variant in Southern California

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks